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Schizophrenia is a serious mental illness with chronic symptoms and significant
impairment in psychosocial functioning, which suggests that it likely has
neurodegenerative characteristics. Inflammatory markers such as pro-inflammatory
cytokines are well-known etiological contributors for psychiatric disorders, including
schizophrenia. Although, the role of inflammation in schizophrenia is becoming evident,
the number of studies in this area is relatively scarce, especially in Lebanon, and
increased procedural thoroughness is needed. Cytokines play a key role in the
activation of the immune system and strongly influence neurotransmission. Previous
investigation of plasma levels showed dysregulation of interleukin (IL)-12. However,
genotypical variations of this interleukin have not been investigated for patients with
schizophrenia yet. Thus, in this paper, we aimed to compute and assess IL-12p40 levels
in the sera of individuals with schizophrenia from different provinces in Lebanon and
compare it to controls. Healthy subjects comprised 60 individuals with a male/female
(M/F) ratio of 31/29, whereas patients with schizophrenia consisted of 63 subjects
with an M/F ratio of 30/33. The mean age for healthy controls was 30 years, whereas
that for patients with schizophrenia was 35 years. A standardized enzyme-linked
immunosorbent assay (ELISA) technique was used to measure the concentration of
IL-12p40 in all collected sera (n = 123). The mean IL-12p40 levels in patients with
schizophrenia were significantly higher than in healthy controls (p = 0.002). Healthy
females had a significantly higher concentration of IL-12p40 than healthy males
(p = 0.009). Female patients with schizophrenia had significantly higher concentrations
of IL-12p40 than their male counterparts (p < 0.001), healthy females (p = 0.018),
and healthy males (p < 0.001), respectively. Male patients with schizophrenia had
significantly higher concentrations of IL-12p40 than healthy males (p = 0.023). The
study’s results suggest that IL-12p40 has a putative role as a potential marker in
schizophrenia and that its elevation may participate in its pathogenesis. IL-12p40 may
be included in a panel to be evaluated in the sera of patients with schizophrenia and an
appreciation of its independent function is important for improving our understanding
of both protective and pathogenic immune responses. Future research should aim to
assess this interleukin and understand its role in other mental illnesses that share a
similar etiology to schizophrenia.
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INTRODUCTION
Schizophrenia is a chronic and often debilitating mental disorder
that affects approximately 1% of the world population. The onset
of full-blown schizophrenia typically occurs in late adolescence
or in early adulthood with a varied symptomatology, which
comprises delusions, hallucinations, negativism, and cognitive
scarcities (American Psychiatric Association, 2013). Even though
several etiological dynamics still need to be clarified, interactions
between genetic vulnerability and environmental stressors in
the primary phases of life are vital in the advancement of
schizophrenia (McDonald and Murray, 2000; Harrison and
Weinberger, 2005). Along with genetic and neurodegenerative
factors, inflammation has also been regarded as a major
causative and/or contributing/mediating factor for schizophrenia
occurrence (Fan et al., 2007).
Inflammation is the first reaction of the immune response, and
it represents a complex reaction by the host to tissue injury such
as infection or physical insult (Nathan, 2002). The main function
of inflammation is to reestablish host homeostasis by allowing
recovery from damage. Given that the adverse repercussions of
the inflammatory progressions may be damaging to the host,
they must be fast, precise, and self-limited (Na et al., 2014).
Immune responses in the body are branded as either innate
or adaptive. Innate immunity is chiefly formed of circulating
effector cells (mast cells, phagocytes, natural killer cells, and
microglia) and its key role is to rapidly eradicate pathogens
in a non-specific way and to commence an adaptive immune
response via exciting antigen-specific T and B lymphocytes
(Na et al., 2014). Meanwhile, adaptive immunity explicitly
distinguishes and recalls pathogens. T helper cells play a vital
part in arbitrating the adaptive immune response. Some have
proposed that naïve T helper cells develop into type 1 T helper
cells (Th1) or type 2 T helper cells (Th2) in response to specific
types of cytokines (Mosmann et al., 1986; Seder and Paul, 1994;
D’Elios and Del Prete, 1998; Na et al., 2014). A cytokine, or
interleukin (IL), is formed of tiny glycoproteins that intercede
signal communications amongst several immune and neuronal
cells throughout the immune response (Na et al., 2014).
Cytokines are formed via outlying immunocompetent cells,
glial cells, and neurons (Woodroofe, 1995; Na et al., 2014). It is
known that Th1 cells are involved in cellular immunity against
intracellular bacteria and viruses, as well as in other autoimmune
diseases such as multiple sclerosis and rheumatoid arthritis (Na
et al., 2014). Contrastingly, Th2 cells direct humoral immunity
against extracellular parasites and allergic reactions (Na et al.,
2014).
Numerous studies have investigated alterations in peripheral
cytokine secretion in schizophrenia (Kim and Maes, 2003; Kim,
2005; Stober et al., 2009). Although, the central nervous system
(CNS) is somehow secluded from the peripheral immune system
by the blood brain barrier (BBB), it is possible for a systemic
peripheral cytokine to invade the BBB and reach the CNS
under normal physiological conditions (Banks, 2005), via several
mechanisms that comprise saturable transport (Banks et al., 1989;
Osburg et al., 2002), disruption of the BBB (Quagliarello et al.,
1991), and through the circumventricular organs that lack the
BBB (Buller, 2001). Pro-inflammatory cytokines such as tumor
necrosis factor-α (TNF-α), IL-6, IL-1β, and interferon-γ (IFN-γ),
formed by persistently actuated macrophages and T lymphocytes
have also been conveyed as immunological altered components
in schizophrenia (Smith and Maes, 1995; Na et al., 2014).
IL-12p40 is identified as a constituent of the bioactive
cytokines IL-12 and IL-23; however, it is not broadly
acknowledged as having inherent functional activity (Trinchieri,
2003; Trinchieri et al., 2003; Hunter, 2005). Nevertheless,
contemporary research has changed this view and backed an
autonomous role for IL-12p40. It is incited excessively over
the other subunits of IL-12 and IL-23 and may be present
in a monomeric or homodimeric form (Mattner et al., 1993;
Gillessen et al., 1995; Gately et al., 1996). It is most commonly
valued for providing a negative feedback loop by competitively
binding to the IL-12 receptor (Mattner et al., 1997). Nevertheless,
IL-12p40 is a chemoattractant for macrophages and stimulates
the migration of bacterially enthused dendritic cells (Shimozato
et al., 2006). It is associated with several pathogenic inflammatory
responses such as silicosis, graft rejection and asthma, but it
has also been shown to be protective in a mycobacterial model
(Abdi, 2002; Ozbey et al., 2008). Appreciating the sovereign
function of IL-12p40 is vital to expand our understanding of
both protective and pathogenic immune responses (Cooper and
Khader, 2007). In patients with schizophrenia, plasma levels of
IL-12 were investigated in two studies (Kim et al., 2002; Ozbey
et al., 2008); these studies showed contradicting results regarding
the IL-12 regulation. However, variations of the IL-12p40
have not been investigated for patients with schizophrenia
yet.
In this article, we aimed to compute and assess IL-12p40
levels in the sera of individuals with schizophrenia from different
provinces in Lebanon and compare it to controls.
MATERIALS AND METHODS
Study Population
Ethical approval for this study was obtained from the
Institutional Review Board of the Lebanese University, Beirut,
Lebanon. Patients originated from different regions of Lebanon
and were recruited from Nabih Berri Governmental University
Hospital and Al-Fanar Psychiatric Hospital. Patients who met
the Diagnostic and Statistical Manual of Mental Disorders (5th
Edn; DSM–5; American Psychiatric Association, 2013) diagnostic
criteria for schizophrenia were recruited. All interviews to assess
diagnosis were carried out by a single trained clinical psychiatrist.
These patients were treated with clozapine antipsychotic
medication. A total of 113 specimens were received, although
only 63 specimens, with a male/female (M/F) ratio of 30/33,
were included in the study following proper enzyme-linked
immunosorbent assay (ELISA) reproducibility (n = 63). Serum
was collected after obtaining personal consent and stored in a
freezer at−80◦C.
Healthy controls were recruited from the same area as
patients with schizophrenia and matched on demographics such
as age, sex, and socioeconomic status. Out of 120 specimens
provided, only 60 specimens with a M/F ratio of 31/29 were
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chosen on the basis of reproducibility in the ELISA test
(n = 60). Control subjects were recruited through advertisement
within the surrounding mental health clinics and hospitals.
Informed, written consent was gained from all participants.
Exclusion criteria for both groups included other psychiatric
and neurological diagnoses. While psychometric testing was not
performed for individual participants, all participating subjects
were educated to at least a secondary school level in Lebanon
or equivalent. None of the participants presented with systemic
illness or signs of fever at the time of sample collection.
Recruited healthy controls did not have a significant physical
disability or disease. The demographic data (male: female
ratio, age range, treatment duration, and daily dose) were also
collected for each group. Neither patients with schizophrenia
nor control subjects were current smokers or suffered from
substance abuse/dependence. All recruited subjects were free
of immunosuppressive medication. Notably, all patients who
attended both hospitals were invited to participate in this study,
and those who opted to participate did so on a voluntary basis; as
such, we were unable to influence demographics, such as age and
sex, of those who took part in this study.
Treatment
The range of treatment duration for patients treated
with clozapine was 6–19 years (with a mean treatment
duration ± standard deviation of 9 ± 3.2 years). The range
for the daily dose of clozapine medication was 100–400 mg per
day (with a mean daily dose± standard deviation of 184± 73 mg
per day), n = 63. We chose to recruit patients treated with
clozapine in the present study primarily for two reasons. Firstly,
patients with a diagnosis of schizophrenia can often be non-
compliant with their prescribed antipsychotic medication (Nosé
et al., 2003). Those treated with clozapine are required to take
the medication daily and monitor the plasma levels of clozapine
regularly. Secondly, clozapine is considered a gold-standard
therapy for treatment-resistant schizophrenia (Williams et al.,
2002).
Cytokine Analysis
The ELISA test was performed according to the user manual
(RayBio Human IL-12p40; RayBiotech, Inc.). All reagents,
samples and standards were brought to room temperature (18–
25◦C) before their use. Each microplate consisted of 96 wells
(12 strips × 8 wells) coated with anti-human IL-12p40. Then,
100 µl of each standard recombinant human IL-12p40 sample
were added into appropriate wells, covered, and incubated for
2.5 h at room temperature, as well as overnight at 4◦C with gentle
shaking. Solutions were discarded and the wells were washed
four times each with 300 µl wash buffer. After the last wash,
the entire remaining wash buffer was aspirated. The plates were
inverted and blotted against clean paper towels. A 100 µl of 1x
biotinylated anti-human IL-12p40 antibody were added to each
well and incubated for 1 h at room temperature with gentle
shaking. The solutions were discarded and washed four times.
A 100 µl of 400-times diluted HRP-conjugated streptavidin were
added to each well and incubated for 45 min at room temperature
with gentle shaking. A 100 µl of Tetramethylbenzidine One-Step
Substrate Reagent were added to each well and incubated for
30 min at room temperature in the dark with gentle shaking.
Finally, 50 µl of Stop solution (0.2 M sulfuric acid) was added to
each well and read immediately at an optical density of 450 nm.
The minimum detectable dose of IL-12p40 was typically less than
10 pg/ml. This method provided high specificity as there is no
cross-reactivity with the remaining cytokines. All specimens were
tested twice and only those that were reproducible were included
in the results. The samples of the cases and the healthy controls
were processed at the same time and in parallel during the same
ELISA.
Statistical Analysis
All statistical analyses were performed with SPSS (Statistical
Package for the Social Sciences) for Windows software version
23 (IBM SPSS, 2015). The Chi square test was used to compare
qualitative variables. For quantitative variables, an independent
samples t-test was used to determine whether the mean difference
of IL-12p40 concentrations in the healthy control group and the
group of patients with schizophrenia is statistically significantly
different to zero. p-values < 0.05 were considered statistically
significant for all analyses.
RESULTS
The average age of healthy controls was 30 years; ages ranged
between 24 and 34 years. The average age of patients with
schizophrenia was 35 years; ages ranged between 29 and 41 years.
Table 1 summarizes the demographic data of studied subjects.
Table 2 summarizes the IL-12p40 concentrations in controls
and individuals with schizophrenia. The mean IL-12p40 levels
in patients with schizophrenia were significantly higher than
in healthy controls (p = 0.002). Healthy females had a
significantly higher concentration of IL-12p40 than healthy males
(p= 0.009). Female patients with schizophrenia had significantly
higher concentrations of IL-12p40 than their male counterparts
(p < 0.001), healthy females (p = 0.018), and healthy males
(p < 0.001), respectively. Male patients with schizophrenia had
significantly higher concentrations of IL-12p40 than healthy
males (p = 0.023). We found no significant associations between
IL-12p40 concentrations and other demographical factors.
Table 3 summarizes the concentrations of IL-12p40 for all the
individuals tested. In healthy controls, the concentration of IL-
12p40 (in ng/ml) of males ranged between 0 and 2.7, while that of
females ranged between 0 and 4.3. In patients with schizophrenia,
the concentration of IL-12p40 in males ranged between 0 and 2.3;
however, that of females ranged between 0.1 and 6.2. Figure 1
depicts this distribution while excluding outliers.
DISCUSSION
This is the first study that measures pro-inflammatory cytokine
levels in patients with schizophrenia in Lebanon, in addition to
the Middle East and North Africa (MENA) region. Our results
reveal a trend toward higher levels of IL-12p40 and, subsequently,
IL-12 in patients with schizophrenia compared to controls.
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TABLE 1 | Demographics of patients with schizophrenia (n = 63) and healthy control subjects (n = 60).
Characteristics Patients with Schizophrenia Healthy Controls
Number Percent Number Percent
Sex
Male 30 47.6 31 51.7
Female 33 52.4 29 48.3
Level of education
Secondary 50 79.4 48 80
Undergraduate 13 20.6 12 20
Hospital
Al-Fanar Psychiatric Hospital 40 63.5 40 66.7
Nabih Berri Governmental University Hospital 23 36.5 20 33.3
Mean SD Mean SD
Age (year)
Males 34 2.6 30 1.9
Females 36 2.4 30 2.2
Treatment
Duration (year) 9 3.2 − −
Clozapine (mg/day) 184 73 − −
SD, standard deviation.
TABLE 2 | Concentration of IL-12p40 (ng/ml) in all studied individuals
(n = 123).
Variables Patients with Schizophrenia
(n = 63)
Healthy Controls
(n = 60)
Males 0.84 ± 0.11 1 0.43 ± 0.12
Females 1.77 ± 0.22 † 1.02 ± 0.18
Total 1.33 ± 0.14 ∗ 0.72 ± 0.12
All values are reported as mean ± standard error of mean. Statistical analyses
were performed by using the independent samples t-tests († significant compared
to males in each group and to healthy females; ∗ significant compared to total
healthy controls; 1 significant compared to healthy males). Significance indicates a
p-value < 0.05 and a 95% Confidence Interval.
The impact of sex on cytokine levels was examined. These
data are in agreement with a previous study, suggesting that
a raised level of cytokines in patients with schizophrenia
predominates in females (O’Connell et al., 2013). Further,
another current study observed that pro-inflammatory cytokines
and body mass index (BMI) were higher in female patients
compared to male patients and controls, aligning with the
idea that visceral fat and altered adipocyte function could
mechanistically explain elevated levels of pro-inflammatory
cytokines in schizophrenia (O’Connell et al., 2014). Bjorling and
Wang (2001) postulated that estrogen may modulate neurogenic
inflammation by interacting with other substances and cells
that participate in the pathogenesis of neurogenic inflammation,
including substance P, bradykinin, and mast cells. Moreover,
Hanamsagar and Bilbo (2015) stated that microglia play a crucial
role in determining the onset and modulation of inflammation
and thus sex differences in microglial function could explain, at
least in part, differences observed in susceptibilities and outcomes
of neurological disorders in men and women. In rodents, females
have significantly more microglia with thick, long processes
than males in sub-regions of the hippocampus as well as in
the amygdala and parietal cortex (Schwarz et al., 2012). Mor
et al. (1999) and Vegeto et al. (2001) added that, in terms of
activation patterns, it has been shown that estrogen can regulate
cytokine expression by microglia at basal level as well as in
the presence of an inflammatory challenge. Testosterone, on
the other hand, is known to have an inhibitory effect on glial
activation (Barreto et al., 2007). Additionally, differences such
as hormonal function, lifestyle and metabolic function may also
play a role in explaining the raised levels of pro-inflammatory
cytokines in females (O’Connell et al., 2014).
Several studies investigating chemokines that seemed to play
an important role in modulating brain functions justify the
bidirectional communications between nervous and immune
system cells and their implications on psychiatric disorders
(Ransohoff et al., 1996; Kronfol and Remick, 2000; Biber
et al., 2002; Garver et al., 2003; Adler and Rogers, 2005;
Cardona et al., 2008; Drexhage et al., 2008; Padmos et al.,
2008). The relationship between several immune factors and the
pathophysiology of schizophrenia has always been a subject of
debate. Studies hypothesized that in patients with schizophrenia
and major mood disorders (Garver et al., 2003; Drexhage et al.,
2008; Padmos et al., 2008), a pro-inflammatory state of the
cytokine network could induce psychopathologic symptoms
and be involved in the pathogenesis and pathophysiology of
these major mental illnesses. Increased serum concentrations
of IL-2, IL-6, and IL-8 have been observed in patients
with schizophrenia (Lin et al., 1998; Zhang et al., 2004).
Moreover, a recent report has shown elevated IL-1β levels
in the cerebrospinal fluids (CSFs) of the patients with drug-
naïve schizophrenia (Söderlund et al., 2009). The elevation
of pro-inflammatory cytokines in patients with schizophrenia
helps us to understand why many patients have conjoint
autoimmune diseases (Saetre et al., 2007; Dantzer et al.,
2008).
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TABLE 3 | The distribution of tested individuals versus concentration of
IL-12p40 (ng/ml) in male and female patients with schizophrenia and
healthy controls (n = 123).
Males Females Males Females
Patients with
Schizophrenia (n = 63)
Healthy Controls
(n = 60)
C
on
ce
nt
ra
tio
n
of
IL
-1
2
p4
0
(n
g/
m
l)
6.2 1
6.1
6
5.9
5.8
5.7
5.6
5.5
5.4
5.3
5.2
5.1
5 1
4.9
4.8
4.7
4.6
4.5
4.4
4.3 1
4.2
4.1
4
3.9 1 1
3.8
3.7
3.6
3.5
3.4 1
3.3 1
3.2
3.1
3
2.9
2.8
2.7 1
2.6 1
2.5
2.4
2.3 1 1 1
2.2 2
2.1 1 1
2 1
1.9 1
1.8 3
1.7 2 1
1.6 2
1.5 2 4 2
1.4 3 4 1
(Continued)
TABLE 3 | Continued
Males Females Males Females
Patients with
Schizophrenia (n = 63)
Healthy Controls
(n = 60)
1.3 1 1 1
1.2 2 1
1.1 1 1
1 4 3
0.9 2 1
0.8 1 1 1
0.7 1 1
0.6 1 2 1 1
0.5 2 2
0.4 1 2
0.3 1 3 4
0.2 3 6 1
0.1 5 1 1 3
0 3 12 3
Our results contradict those reported by Kim et al. (2002),
which suggest that Th1 cytokines such as IL-2 and IL-12 are
decreased in schizophrenia, but conform to those reported by
Ozbey et al. (2008) that demonstrate a significant elevation
of IL-12. Subsequent studies add that Th2 cytokines, such as
IL-10, are augmented (Kim et al., 2002; Maes et al., 2002).
Founded on the dichotomous notion of an adaptive immune
response, the theory of Th1/Th2 imbalance was proposed as
a potential mechanism (Schwarz et al., 2001). Another study
by Miller et al. (2011) reported similar findings to ours. They
established that pro-inflammatory cytokine levels are constantly
augmented in patients with schizophrenia and stated that pro-
inflammatory cytokines like IL-6, IL-12, TNF-α, IL-1β, and IFN-γ
are elevated in the blood and CSF in initial-onset and acute-
relapse patients with schizophrenia (Miller et al., 2011; Na et al.,
2014). The outcomes of many recent publications have reinforced
the function of pro-inflammatory cytokines in schizophrenia.
Saetre et al. (2007) conveyed that an inflammation linked gene
is augmented in schizophrenia. Additionally, Söderlund et al.
(2009) reported that IL-1β is expressively augmented in the
CSF of those with schizophrenia when compared to healthy
volunteers.
Levels of pro-inflammatory cytokines have been shown to be
increased not only in patients with schizophrenia but also in
patients with bipolar disorder. After performing a comprehensive
analysis of inflammatory molecules involved in schizophrenia
and bipolar disorder, Dimitrov et al. (2011) speculated that
dysregulation of a particular set of cytokines may lead to
schizophrenia, while another set may lead to depression or
bipolar disorder.
As described in Figure 1, the levels of IL-12p40 were
moderately high in healthy individuals. Personal, familial,
and societal stressors that affect Lebanese individuals could
have contributed to these elevated cytokine levels (Fares
et al., 2014; Hoteit and Fares, 2014). The socioeconomic
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FIGURE 1 | A Box-and-Whisker plot showing the distribution of tested
individuals versus concentration of IL-12p40 (ng/ml) in males and
females of patients with schizophrenia (n = 63) and healthy controls
(n = 60); outliers were excluded from the plot.
and political situation in Lebanon, along with the regional
instability and the numerous conflicts that the Lebanese
people have witnessed, contributes to a higher degree of
neuropsychological stress and anxiety (Fares and Fares, 2013;
Fares et al., 2013a,b).
Strengths and Limitations
This is the first study to measure pro-inflammatory cytokine
levels in patients with schizophrenia in Lebanon and the
MENA region. This study succeeds in showing that the
levels of IL-12p40 are significantly elevated in patients with
schizophrenia. However, the sample size and the lack of
proper medical records (biochemical data and cardiovascular
disease risk factors) for the participants can be considered
as limitations of the study results. Cytokine levels in serum
or plasma are confounded by a number of conditions,
such as age, sex, socioeconomic status (O’Connor et al.,
2009), metabolic syndrome and visceral obesity (Weisberg
et al., 2003; Xu et al., 2003), smoking (De Leon et al.,
2002), physical activity (Pledge et al., 2011), poor-rated self-
health (Janszky et al., 2005; Christian et al., 2011), and
medication (Miller et al., 2011). In our study, we succeeded
in controlling many confounders as healthy controls were
recruited from the same area as patients with schizophrenia;
both groups were comparable in demographics such as age,
sex, medical history, smoking history, and socioeconomic
status.
Future Research
For a greater understanding of the etiology and pathophysiology
of schizophrenia, further studies in this field are urgently needed
to widely assess the actual status of cytokines in a population
with high predisposition to varied mental and psychiatric
disorders. Additionally, therapeutic strategies for schizophrenia
that target the inhibition of specific pro-inflammatory cytokine
(such as IL-12p40) activation could be further explored. Future
research should also aim to assess IL-12p40 and understand its
role in other mental illnesses that share a similar etiology to
schizophrenia.
CONCLUSION
The current study examined the levels of IL-12p40 in 63 patients
with schizophrenia treated with antipsychotic medication, as well
as 60 healthy controls. Patients diagnosed with schizophrenia
showed significantly elevated levels of IL-12p40 compared to
controls. Healthy females had significantly higher concentrations
than healthy males. Female patients with schizophrenia had a
significantly higher concentration of IL-12p40 than their male
counterparts and healthy controls, respectively. Male patients
with schizophrenia had a significantly higher concentration of
IL-12p40 than healthy males. The results of this study suggest
that IL-12p40 has a putative role as a potential marker in
schizophrenia and that its dysregulation may participate in
the pathogenesis of schizophrenia. IL-12p40 may be included
in a panel to be evaluated in the sera of patients with
schizophrenia.
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